Nektar Therapeutics (NKTR) analyst forecast and price target
Analyst forecast
Consensus of 11 analyst ratings
Based on 7 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| UBS | Initiated Coverage | Neutral | $53.00 | Oct 12, 2026 |
| Leerink Partners | Initiated Coverage | Outperform | $130.00 | Oct 12, 2026 |
| BTIG | Maintained | Buy | $178.00 | Oct 9, 2026 |
| Raymond James | Initiated Coverage | Market Perform | — | Oct 9, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $185.00 | Oct 2, 2026 |
| BTIG | Maintained | Buy | $178.00 | Sep 28, 2026 |
| BTIG | Maintained | Buy | $178.00 | Sep 25, 2026 |
| Wedbush | Maintained | Neutral | $50.00 from $80.00 | Sep 23, 2026 |
| BTIG | Maintained | Buy | $178.00 | Sep 16, 2026 |
| BTIG | Maintained | Buy | $178.00 | Sep 9, 2026 |
| JP Morgan | Maintained | Neutral | $65.00 | Aug 21, 2026 |
| Canaccord Genuity | Initiated Coverage | Buy | $153.00 | Jul 22, 2026 |
| Wedbush | Maintained | Neutral | $80.00 from $95.00 | May 11, 2026 |
| Piper Sandler | Maintained | Overweight | $192.00 from $105.00 | May 8, 2026 |
| Wedbush | Maintained | Neutral | $95.00 from $70.00 | Apr 21, 2026 |
| Citigroup | Maintained | Buy | $151.00 from $123.00 | Apr 21, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $185.00 from $165.00 | Apr 20, 2026 |
| BTIG | Maintained | Buy | $178.00 from $151.00 | Apr 20, 2026 |
| Wedbush | Initiated Coverage | Neutral | $70.00 | Mar 24, 2026 |
| TD Cowen | Initiated Coverage | Buy | — | Mar 17, 2026 |
Frequently asked questions
What is the price target for NKTR stock?
The average 12-month analyst price target for Nektar Therapeutics (NKTR) is $116.29, with a high estimate of $185.00 and a low of $50.00, across 7 analysts.
Is NKTR a buy, sell, or hold?
Analysts covering Nektar Therapeutics currently average a Buy rating: 10 buy, 1 hold and 0 sell, from 11 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for NKTR?
The average price target of $116.29 implies 214.88% upside from the last price of $36.93.
What is the latest analyst rating on NKTR?
On Oct 12, 2026, UBS initiated coverage of Nektar Therapeutics at Neutral with a price target of $53.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.